Advanced Magnetics' Combidex MRI contrast agent aids in the non-invasive evaluation of lymph nodes in prostate cancer patients, according to clinical data published in this week's New England Journal of Medicine. Researchers from the Massachusetts General Hospital and University Medical Center Nijmegen in the Netherlands concluded that Combidex-enhanced MRI allows for the detection of small and otherwise undetectable lymph node metastases in prostate cancer patients, according to Advanced Magnetics of Cambridge, MA, and marketing partner Cytogen of Princeton, NJ.
By AuntMinnie.com staff writersJune 19, 2003
Related Reading
ASNR papers highlight Combidex for tumor imaging, April 30, 2003
Advanced Magnetics falls into red in Q1, January 16, 2003
Advanced Magnetics revenues decline, November 25, 2002
NCI to study Advanced Magnetics agents, October 1, 2002
Copyright © 2003 AuntMinnie.com